Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22959001 | 0.87 | ALDH1A1 (0.39) | CYP2D6CYP2C19MTNR1AMTNR1BMAPK1 | |
| SCHEMBL10062233 | 0.83 | MTNR1A (0.44) | CYP2D6CYP2C19MTNR1AMTNR1BMAPK1 | |
| SCHEMBL14953743 | 0.82 | ALDH1A1 (0.39) | CYP2D6CYP2C19MTNR1AMTNR1BMAPK1 | |
| SCHEMBL8436494 | 0.82 | TSHR (0.42) | CYP2D6CYP2C19MTNR1AMTNR1BMAPK1 | |
| SCHEMBL21165837 | 0.81 | CYP2D6 (0.41) | CYP2D6CYP2C19MTNR1AMTNR1BMAPK1 | |
| SCHEMBL12117405 | 0.80 | CYP2D6 (0.38) | CYP2D6CYP2C19MAPK1ANPEPDNPEP | |
| SCHEMBL20440215 | 0.79 | ALDH1A1 (0.43) | CYP2D6CYP2C19MTNR1AMTNR1BMAPK1 | |
| SCHEMBL14094259 | 0.78 | KDM4E (0.54) | MTNR1AMTNR1BMAPK1KDM4EHIF1A | |
| SCHEMBL21750018 | 0.78 | GABRP (0.45) | CYP2D6CYP2C19MTNR1AMTNR1BANPEP | |
| SCHEMBL5092791 | 0.78 | GABRP (0.45) | CYP2D6CYP2C19MTNR1AMTNR1BANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-8455654-B2 | Nanosized particles of benzimidazolone pigments | XEROX CORPORATION (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110271874-A1 | Nanosized Particles of Benzimidazolone Pigments | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2011-11-10 | — | — | US | disclosed |
| US-8012254-B2 | Nanosized particles of benzimidazolone pigments | XEROX CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-7883574-B2 | Methods of making nanosized particles of benzimidazolone pigments | XEROX CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-7857901-B2 | Nonpolar liquid and solid phase change ink compositions comprising nanosized particles of benzimidazolone pigments | XEROX CORPORATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100251928-A1 | NONPOLAR LIQUID AND SOLID PHASE CHANGE INK COMPOSITIONS COMPRISING NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS | XEROX CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100104963-A1 | NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS | XEROX CORPORATION (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100004360-A1 | METHODS OF MAKING NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS | XEROX CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230313195-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | PCSK9, PCSK7, PCSK6 | CYP2D6 1689/4885CYP2C19 1563/4885MTNR1A 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.